Sourabh Aggarwal, MD
Interventional Cardiology · Phoenix, AZNPI 1154677417
Payments from drug & device makers
Across 227 payments — averaging $127.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$20K
- Penumbra, Inc.$2K
- Abbott$1K
- Medtronic$1K
- Novartis$852
- Abiomed$674
- plus $4K from 30 others
What the payments were for
- Travel & lodging$9213%
- Food & beverage$8,20928%
- Other$19,91769%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $20,008 |
| Penumbra, Inc. | 4 | $1,511 |
| Abbott | 27 | $1,326 |
| Medtronic(2 entities) | 12 | $1,057 |
| Novartis | 43 | $852 |
| Abiomed | 11 | $674 |
| Merck | 24 | $550 |
| Edwards Lifesciences | 13 | $536 |
| Boston Scientific | 11 | $457 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $348 |
| Johnson & Johnson | 4 | $164 |
| Shockwave Medical, Inc | 2 | $141 |
| Biosense Webster, Inc. | 4 | $137 |
| AstraZeneca | 3 | $135 |
| E.r. Squibb & Sons, L.L.C. | 9 | $133 |
| Boehringer Ingelheim | 3 | $132 |
| Amgen | 7 | $124 |
| Pfizer | 6 | $110 |
| Chiesi USA, Inc. | 5 | $81 |
| Cleerly, Inc. | 1 | $64 |
| Cardinal Health 200 LLC | 2 | $56 |
| Philips North America LLC | 3 | $55 |
| Cardiovascular Systems Inc. | 1 | $48 |
| ZOLL Respicardia, Inc. | 2 | $46 |
| Inspire Medical Systems, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Novo Nordisk | 2 | $35 |
| Stryker | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Inari Medical, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Cook Medical LLC | 1 | $13 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$19,917
- RUBY Coil$1,279
- CoreValve Evolut$436
- Edwards SAPIEN 3 Transcatheter Heart Valve$280
- Indigo System$231
- Impella$219
- JOT DX$183
- Resolute$168
- MitraClip$163
- LifeVest$159
- Perclose ProStyle$153
- COREVALVE EVOLUT R$142
- Optis Coronary Imaging System$123
- RESOLUTE ONYX$119
- SYNERGY$114
- XARELTO$111
- FARXIGA$104
- LUX-DX$103
How this compares
$29,047 in reported general payments places this provider in the 65th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 260 | $291,708 |
| JardianceEmpagliflozin | 69 | $84,753 |
| EntrestoSacubitril/Valsartan | 57 | $62,780 |
| XareltoRivaroxaban | 41 | $45,321 |
| Repatha SureclickEvolocumab | 48 | $43,968 |
| FarxigaDapagliflozin Propanediol | 13 | $16,336 |
| BrilintaTicagrelor | 16 | $13,021 |
| Carvedilol | 296 | $2,518 |
| ClopidogrelClopidogrel Bisulfate | 227 | $2,508 |
| Metoprolol Succinate | 217 | $2,462 |
| Atorvastatin Calcium | 286 | $2,451 |
| Ezetimibe | 113 | $2,260 |
| Rosuvastatin Calcium | 119 | $2,240 |
| Bumetanide | 41 | $1,814 |
| Losartan Potassium | 213 | $1,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $110 | $291,708260 claims |
| Boehringer IngelheimJardiance | $132 | $84,75369 claims |
| NovartisEntresto | $852 | $62,78057 claims |
| Johnson & JohnsonXarelto | $164 | $45,32141 claims |
| AstraZenecaFarxiga, Brilinta | $135 | $29,35729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$8.8M
- Timothy ByrnePhoenix$2.1M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Akil LoliPhoenix$506K
- Haidar YassinPhoenix$457K
- Michael WhitePhoenix$417K
- Nezar FallujiPhoenix$348K
- Floyd FortuinPhoenix$263K
- Nishant GuptaPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.